Nausea and vomiting medical therapy

Jump to navigation Jump to search

Nausea and vomiting Microchapters


Patient Information


Historical Perspective




Differentiating Nausea and Vomiting from other Conditions

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


X Ray



Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nausea and vomiting medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Nausea and vomiting medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nausea and vomiting medical therapy

CDC on Nausea and vomiting medical therapy

Nausea and vomiting medical therapy in the news

Blogs on Nausea and vomiting medical therapy

Directions to Hospitals Treating Nausea and vomiting

Risk calculators and risk factors for Nausea and vomiting medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: {{VVS}


Mainstay of treatment of nausea and vomiting is correcting any electrolyte imbalance, dehydration, malnutrition, and suppression of symptoms while evaluating and treating the underlying cause. Dietary recommendations include a low-fat, low-fiber diet with frequent small meals if able to tolerate oral intake. Liquid diet is recommended in case solid diet is not well tolerated. Medical therapy involves two groups of drugs i.e., antiemetics and prokinetics. Antiemetics suppress nausea and vomiting and typically act centrally. Prokinetics modulate gastrointestinal motility.

Medical Therapy



Miscellaneous therapy


  1. 1.0 1.1 Hasler WL, Chey WD (December 2003). "Nausea and vomiting". Gastroenterology. 125 (6): 1860–7. doi:10.1053/j.gastro.2003.09.040. PMID 14724837.
  2. 2.0 2.1 Singh P, Yoon SS, Kuo B (January 2016). "Nausea: a review of pathophysiology and therapeutics". Therap Adv Gastroenterol. 9 (1): 98–112. doi:10.1177/1756283X15618131. PMC 4699282. PMID 26770271.
  3. Di Florio T, Goucke R (August 1993). "Reduction of dopamine release and postoperative emesis by benzodiazepines". Br J Anaesth. 71 (2): 325. doi:10.1093/bja/71.2.325. PMID 8123420.
  4. Flake ZA, Scalley RD, Bailey AG (March 2004). "Practical selection of antiemetics". Am Fam Physician. 69 (5): 1169–74. PMID 15023018.
  5. 5.0 5.1 Quigley EM, Hasler WL, Parkman HP (January 2001). "AGA technical review on nausea and vomiting". Gastroenterology. 120 (1): 263–86. doi:10.1053/gast.2001.20516. PMID 11208736.
  6. Golding JF, Stott JR (June 1997). "Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate". Br J Clin Pharmacol. 43 (6): 633–7. doi:10.1046/j.1365-2125.1997.00606.x. PMC 2042789. PMID 9205824.
  7. Sanger GJ, Andrews PL (October 2006). "Treatment of nausea and vomiting: gaps in our knowledge". Auton Neurosci. 129 (1–2): 3–16. doi:10.1016/j.autneu.2006.07.009. PMID 16934536.
  8. 8.0 8.1 8.2 Chepyala P, Olden KW (April 2008). "Nausea and vomiting". Curr Treat Options Gastroenterol. 11 (2): 135–44. doi:10.1007/s11938-008-0026-6. PMID 18321441.
  9. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (June 1979). "Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy". N Engl J Med. 300 (23): 1295–7. doi:10.1056/NEJM197906073002302. PMID 375088.
  10. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N (June 2004). "A factorial trial of six interventions for the prevention of postoperative nausea and vomiting". N Engl J Med. 350 (24): 2441–51. doi:10.1056/NEJMoa032196. PMC 1307533. PMID 15190136.
  11. Madsen JL, Fuglsang S (April 2008). "A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans". Aliment Pharmacol Ther. 27 (7): 609–15. doi:10.1111/j.1365-2036.2008.03618.x. PMID 18208572.
  12. Curran MP, Robinson DM (2009). "Aprepitant: a review of its use in the prevention of nausea and vomiting". Drugs. 69 (13): 1853–78. doi:10.2165/11203680-000000000-00000. PMID 19719336.
  13. Chong K, Dhatariya K (May 2009). "A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant". Nat Rev Endocrinol. 5 (5): 285–8. doi:10.1038/nrendo.2009.50. PMID 19444262.
  14. Javid FA, Bulmer DC, Broad J, Aziz Q, Dukes GE, Sanger GJ (January 2013). "Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors". Eur J Pharmacol. 699 (1–3): 48–54. doi:10.1016/j.ejphar.2012.11.035. PMID 23201066.
  15. Tack J, Janssens J, Vantrappen G, Peeters T, Annese V, Depoortere I, Muls E, Bouillon R (July 1992). "Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis". Gastroenterology. 103 (1): 72–9. doi:10.1016/0016-5085(92)91097-n. PMID 1612359.
  16. Prakash C, Lustman PJ, Freedland KE, Clouse RE (September 1998). "Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients". Dig Dis Sci. 43 (9): 1951–6. doi:10.1023/a:1018878324327. PMID 9753257.
  17. Guttuso T (August 2014). "Gabapentin's anti-nausea and anti-emetic effects: a review". Exp Brain Res. 232 (8): 2535–9. doi:10.1007/s00221-014-3905-1. PMID 24668130.
  18. Guttuso T, Vitticore P, Holloway RG (March 2005). "Responsiveness of life-threatening refractory emesis to gabapentin-scopolamine therapy following posterior fossa surgery. Case report". J Neurosurg. 102 (3): 547–9. doi:10.3171/jns.2005.102.3.0547. PMID 15796394.
  19. Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W (July 2005). "A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study". Support Care Cancer. 13 (7): 529–34. doi:10.1007/s00520-004-0755-6. PMID 15700131.
  20. Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL, Loehrer P (2004). "A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study". Cancer Invest. 22 (3): 383–8. doi:10.1081/cnv-200029066. PMID 15493359.
  21. Ernst E, Pittler MH (March 2000). "Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials". Br J Anaesth. 84 (3): 367–71. doi:10.1093/oxfordjournals.bja.a013442. PMID 10793599.
  22. Keating A, Chez RA (2002). "Ginger syrup as an antiemetic in early pregnancy". Altern Ther Health Med. 8 (5): 89–91. PMID 12233808.
  23. McCallum RW, Dusing RW, Sarosiek I, Cocjin J, Forster J, Lin Z (February 2010). "Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients". Neurogastroenterol Motil. 22 (2): 161–7, e50–1. doi:10.1111/j.1365-2982.2009.01389.x. PMID 19719511.
  24. Elvir-Lazo OL, White PF, Yumul R, Cruz Eng H (2020). "Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review". F1000Res. 9. doi:10.12688/f1000research.21832.1. PMC 7429924 Check |pmc= value (help). PMID 32913634 Check |pmid= value (help).
  25. Marchioro G, Azzarello G, Viviani F, Barbato F, Pavanetto M, Rosetti F, Pappagallo GL, Vinante O (August 2000). "Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy". Oncology. 59 (2): 100–4. doi:10.1159/000012144. PMID 10971166.
  26. Lee A, Fan LT (April 2009). "Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting". Cochrane Database Syst Rev (2): CD003281. doi:10.1002/14651858.CD003281.pub3. PMC 3113464. PMID 19370583.

Template:WH Template:WS